https://www.yiliao.com/index.php?action=history&feed=atom&title=%E6%B5%B7%E7%9B%8A%E5%9D%A6
海益坦 - 版本历史
2026-04-18T07:02:08Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E6%B5%B7%E7%9B%8A%E5%9D%A6&diff=314595&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T02:30:38Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[海益坦]]</strong>（<strong>[[海益坦®]]</strong>，通用名：<strong>[[谷美替尼]]</strong>/<strong>[[Vebreltinib]]</strong>）是中国自主研发的一种具有全球知识产权的高选择性口服<strong>[[MET]]</strong>激酶抑制剂。作为一种强效的[[小分子]]酪氨酸激酶抑制剂（[[TKI]]），[[海益坦]]通过高度特异性地结合[[MET]]蛋白的[[ATP]]结合位点，阻断由[[肝细胞生长因子]]（[[HGF]]）介导的信号级联反应。临床上，该药主要用于治疗携带<strong>[[MET14外显子跳变]]</strong>（[[METex14 skipping]]）的局部晚期或转移性<strong>[[非小细胞肺癌]]</strong>（[[NSCLC]]）。凭借其显著的客观缓解率、卓越的[[血脑屏障]]穿透能力以及良好的耐受性，[[海益坦]]已成为[[MET]]驱动型肺癌精准治疗的一线核心药物。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[海益坦]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">海益坦® / 谷美替尼 · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[MET]]抑制剂结合模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">批准适应症：[[METex14]] [[NSCLC]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">通用名</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[谷美替尼]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发代码</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[SCC-244]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">核心靶点</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[MET]] (c-Met)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药途径</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[口服]] (片剂)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发企业</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[海和药物]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">上市状态</th><br />
<td style="padding: 12px; color: #0f172a;">[[NMPA]]批准上市</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：深度抑制MET驱动信号</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[海益坦]]的抗肿瘤活性源于其对[[MET]]致癌信号轴的精准物理阻断：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>高选择性ATP竞争：</strong> [[海益坦]]在分子结构上经过优化，能以极高的亲和力占据[[MET]]激酶催化域的[[ATP]]结合位点，从而阻断其[[磷酸化]]激活。相较于非选择性抑制剂，它能减少对[[VEGFR]]等其它激酶的误伤，降低[[高血压]]等副作用。</li><br />
<li style="margin-bottom: 12px;"><strong>克服METex14致癌性：</strong> [[MET14外显子]]编码的蛋白区域负责招募[[Cbl泛素连接酶]]。跳变突变导致[[MET]]受体泛素化降解失败，使其在细胞膜上持续存在。[[海益坦]]能够强效抑制这些“[[不死受体]]”引发的下游信号。</li><br />
<li style="margin-bottom: 12px;"><strong>中枢神经系统覆盖：</strong> 药代动力学研究显示[[海益坦]]具有显著的[[血脑屏障]]穿透性，能够达到颅内治疗浓度，对[[脑转移]]病灶产生深度打击。</li><br />
</ul><br />
<br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床图谱：GLORY研究详析</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">评价维度</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">研究发现</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[客观缓解率]](ORR)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">全人群 [[ORR]] 超过 60%。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">证实其作为 [[MET]] 突变患者强效干预手段的价值。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[脑转移控制]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">颅内病灶缩小率显著。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">解决了肺癌脑转移这一临床诊疗难点。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[安全性]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">不良反应多为1-2级，主要是[[外周水肿]]。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">具有良好的长期服药依从性和安全性特征。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：全程管理与副作用干预</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
应用[[海益坦]]需结合精准检测与全程支持治疗：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>分子筛查为先：</strong> 启动治疗前必须通过[[NGS]]、[[RT-PCR]]或[[FISH]]检测确认<strong>[[MET14外显子跳变]]</strong>。此外，对于[[MET扩增]]引起的[[EGFR-TKI]]耐药，[[海益坦]]联合疗法也是目前重要的探索方向。</li><br />
<li style="margin-bottom: 12px;"><strong>[[外周水肿]]管理：</strong> 它是[[MET]]抑制剂的类效应。临床建议通过[[弹力袜]]、抬高患肢或适量使用[[利尿剂]]进行干预，通常不需停药。</li><br />
<li style="margin-bottom: 12px;"><strong>耐药监测：</strong> 若病情进展，建议行二次[[液体活检]]监测[[MET]]激酶域[[获得性突变]]（如[[D1228]]、[[Y1230]]）或其它代偿通路（如[[KRAS]]扩增）的出现。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[MET14外显子跳变]]：</strong> [[NSCLC]]中约占3%-4%的致癌驱动变异，是[[海益坦]]的精准打击靶点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[谷美替尼]]：</strong> [[海益坦]]的通用名，体现了其化学结构分类与激酶选择性。</li><br />
<li style="margin-bottom: 8px;"><strong>[[海和药物]]：</strong> [[海益坦]]的原研企业，中国创新药领域的代表性初创Biotech。</li><br />
<li style="margin-bottom: 8px;"><strong>[[赛沃替尼]] (Savolitinib)：</strong> 同类[[MET]]抑制剂，常与[[海益坦]]在临床路径中进行比较。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Lu S, et al. (2023).</strong> <em>Vebreltinib (SCC-244) in patients with advanced NSCLC harboring MET exon 14 skipping mutations (GLORY): a multicenter, open-label, phase 2 study.</em> <strong>[[The Lancet Respiratory Medicine]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：GLORY研究是确立谷美替尼临床地位的核心证据，证明了其在中国及全球人群中的高效与安全性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Zhang T, et al. (2022).</strong> <em>Preclinical characterization and structural basis for the high selectivity of Vebreltinib.</em> <strong>[[Molecular Cancer Therapeutics]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：该研究揭示了海益坦分子如何在原子水平精准识别MET激酶口袋，为其临床的高选择性提供了药理学依据。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[海益坦]] ([[Vebreltinib]]) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[MET]]•[[HGF]]•[[EGFR]]•[[KRAS]]•[[ALK]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类/竞争</td><br />
<td style="padding: 10px 15px; color: #334155;">[[赛沃替尼]]•[[卡马替尼]] (Capmatinib)•[[特泊替尼]] (Tepotinib)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[海和药物]]•[[NMPA]]•[[上海胸科医院]]•[[CSCO]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;">[[克服MET获得性耐药]]•[[针对MET扩增的联合用药]]•[[海益坦在消化道肿瘤中的应用]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164